Skip to main content
OpenTrials
Completed

NCT Number: NCT01489813

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

Patients with non-invasive bladder cancer are often treated with intravesical therapy in order to prevent the recurrence of bladder cancer. Intravesical therapy can cause many lower urinary tract symptoms, which can limit the dose of therapy and therefore efficacy of treatment. There have been a number of studies that suggest a chemical found in soy beans may be able to help with these side effects. This chemical is called genistein and can be extracted and given to study subjects in pill form. In this study, the investigators would like to have patients placed into two different groups. One group would take genistein and the other group would take a placebo, a sugar pill that looks like the genistein pill. In doing this study the investigators hope to explore the findings from other studies to see if lower urinary tract symptoms are reduced and to see if recurrence rates for patients are affected by genistein. The study would take about four and a half months total.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bladder Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Neoplasms Neoplasms by Site Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

Loading trial locations.

About this study

Patients who are treated with bacillus Calmette-Guerin (BCG) intravesical therapy for non-muscle invasive (TaT1) Tis superficial bladder cancer often develop adverse effects (urinary tract symptoms) which limit the dose (and therefore the efficacy) of therapy and result in poor quality of life. Genistein is a nutritional supplement with anti-inflammatory properties which might help alleviate adverse effects of intravesical therapy that are due to inflammation. Additionally, genistein also has anti-tumor and immunopotentiating properties and has been shown to have no known side effects. Our hypothesis is that genistein given together with BCG intravesical therapy will reduce its adverse effects and improve the efficacy of therapy. Patients (N=88) scheduled for intravesical therapy will be randomly assigned to take 30 mg tablets PO TID of genistein supplement (N=44) or placebo (N=44) during therapy and one month post therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female gender
  • 18 years or older
  • Diagnosis of superficial bladder cancer
  • Scheduled for induction BCG intravesical therapy
  • Willing and able to give blood sample
  • Willing and able to fill out a pill diary to ensure compliance
  • Willing and able to sign informed consent
  • Birth control is not required for this study!

Exclusion criteria

  • Patients who are pregnant
  • Diagnosis of muscle-invasive bladder cancer
  • Unwillingness to follow study protocol and compliance procedures
  • HIV positive or immunocompromised
  • Receiving concurrent immunotherapy or chemotherapy
  • Presence of concurrent second cancer (active, not history)

Treatment and study plan

Genistein

Drug

30 mg of genistein supplement by mouth three times daily (PO TID).

Other names: Bonistein, I-Cool®

Sugar pill

Drug

Sugar pills will be taken by mouth three times daily (PO TID).

Other names: Placebo pills

Primary outcomes

  1. Change in Severity of Urinary Symptoms as Determined by the The International Prostate Symptom Score (IPSS) Questionnaire Score.

    Time frame: At baseline and after 6 weeks of treatment

    The change in severity of urinary symptoms as determined by the International Prostate Symptom Score (IPSS) questionnaire score. IPSS scores at 6 weeks of treatment will be compared to scores at baseline of treatment. Lower values indicate a better outcome.

    0 to 7 points: Mild symptoms 8 to 19 points: Moderate symptoms 20 to 35 points: Severe symptoms

Secondary outcomes

  1. Number of Participants With Cancer Recurrence Determined at 10-week Biopsy.

    Time frame: At 10 weeks of treatment.

    A secondary study endpoint will be the presence of cancer and the rate of recurrence as determined by the 10-week biopsy or subsequent standard follow-up visits.

Sponsors and collaborators

Lead sponsor

Emory University

Other

Collaborators

  • National Cancer Institute (NCI)
  • National Institutes of Health (NIH)
  • dsm-firmenich Switzerland AG

Registry information

Official study title

Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy

Important dates

Study start
2017
Primary completion
2023
Study completion
2024
First posted
Dec 12, 2011
Registry last updated
Feb 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.